Published in Cancer Weekly, December 10th, 2002
Analysis of results from the first 414 women in the prepivotal study indicates that the SpectRx device detected 16% more high-grade precancers than Pap tests, the majority of which were the thin layer Pap tests. These results suggest that the SpectRx device could reduce by more than half the 2.2 million unnecessary follow up colposcopic exams and 1.6 million unnecessary biopsies resulting from uncertain or false positive Pap test results. In the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.